Drug Trial Radar · NCT00513604
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Jun 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Jun 2007
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Aug 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: * Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors. * An adaptive cell transfer therapy has been pioneered, in which cells are grown for a short time in the laboratory. The way they are grown may have a better effect in a patient's body than do other cells that are cultured for a longer time. Objectives: * To determine whether tumor-infiltrating lymphocytes (TIL) can be put in cells removed from patients' tumors or blood and then reinfused, with the purpose of shrinking tumors. * To evaluate safety and effectiveness of the treatment. Eligibility: * Patients 18 years of age or older with metastatic cancer melanoma (cancer that has spread beyond the original site). * Patient's leukocyte antigen type is human leukocyte antigens (HLA-A) 0201. Design: -Patients undergo the following procedures: * Leukapheresis (on two occasions). This is a method of collecting large numbers of white blood cells. The cells obtained in the first leukapheresis procedure are grown in the laboratory, and the TIL cells (called young TIL cells) are inserted into the cells using an inactivated (harmless) virus in a process called retroviral transduction. Cells collected in the second leukapheresis procedure are used to evaluate the effectiveness of the study treatment. * Chemotherapy. Patients are given chemotherapy through a vein (intravenously, IV) over 1 hour for 2 days to suppress the immune system so that the patient's immune cells do not interfere with the treatment. * Treatment with young TIL cells. Patients receive an IV infusion of the treated cells, followed by infusions the drug aldesleukin-2 (IL-2), which helps boost the effectiveness of the treated white cells. * Patients are given support medications to prevent complications such as infections. * Patients may undergo a tumor biopsy (removal of a small piece of tumor tissue). * Patients are evaluated with laboratory tests and imaging tests, such as computed tomography (CT) scans, 4 to 6 weeks after treatment and then once a month for 3 to 4 months to determine the response to treatment. * Patients have blood tests at 3, 6, and 12 months and then annually for 5 years.
Conditions
- Melanoma
- Malignant Melanoma
- Melanoma, Experimental
- Experimental Melanomas
Interventions
aldesleukinBiological
Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
therapeutic autologous lymphocytesBiological
Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
CyclophosphamideDrug
Given intravenously 60 mg/kg/day, day -7 to -6
Fludarabine phosphateDrug
Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
Total body irradiationRadiation
600 cGy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical ResponseTime frame: every 1-3 months until disease progression. Total length of time -8/7/2007 to 9/27/2012
- ToxicityTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.